Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Organisation › Details

Cullinan Oncology (Group)

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, the company’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. Cullinan is backed by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures. *

 

Period Start 2017-10-03 existent
Product Industry antibody cancer drug
Persons Person Hughes, Owen (MPM Capitap 201710 Managing Director + Cullinan Oncology 201710– CEO before Intarcia + 16y at Wall Street)
  Person 2 Bäuerle, Patrick (MPM Capital 201710 Managing Director formerly Micromet)
     
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2018-10-31

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Cullinan Oncology (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top